The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer
International Journal of Cancer · 15.08.2026 · 159 (4) · 1056-1067
DOI: 10.1002/ijc.70490 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 10.04.2026. Verfasst von Layla Andour und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Antineoplastic Agents, Hormonal, Stromal Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bollenstreekfonds, Lisse.
Abstract (Originalsprache)
Approximately 75% of breast cancers are hormone receptor‐positive (HR+). Endocrine therapy may be administered to improve survival. Neoadjuvant therapy may enable breast‐ and axilla‐conserving surgery, but identifying who will benefit remains challenging. This study evaluates the predictive value of the tumor‐stroma ratio (TSR) for response to neoadjuvant endocrine therapy (NET) and examines the accuracy of MRI in predicting (near) pathological complete response (pCR). Women diagnosed between 2014 and 2024 with invasive HR+, human epidermal growth factor 2‐negative breast cancer who received NET in two Dutch hospitals were included. A total of 208 women (215 tumors) were included, of whom 81 (37.7%) had a stroma‐low tumor and 134 (62.3%) stroma‐high. Almost 1 out of 4 stroma‐low cases achieved (near) pCR after NET. In both univariable (OR 2.85, 95% CI 1.32–6.15, p = 0.008) and multivariable analysis (OR 3.70, 95% CI 1.54–8.90, p = 0.003), stroma‐low tumors showed an increased likelihood of achieving (near) pCR compared to stroma‐high tumors. In node‐positive patients ( n = 117), univariable analysis presented higher odds of pCR in the axilla after NET in the stroma‐low group (OR 4.41, 95% CI 1.08–18.08, p = 0.039), although this was not significant in multivariable analysis ( p = 0.060). The MRI correctly reported (near) pCR in 12 (75%) stroma‐low cases and 8 (35%) stroma‐high. Stroma‐low patients significantly more often achieved (near) pCR of the tumor and axilla after NET compared to stroma‐high patients. The accuracy of MRI to predict (near) pCR was higher in the stroma‐low group compared to the stroma‐high group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Pathology, Haaglanden Medical Center, The Hague, the Netherlands.
- Department of Surgery, Medical Center Haaglanden, The Hague, the Netherlands.
ORCID-Profile: Layla Andour, Sophie C Hagenaars, Anne Florine de Groot
Förderung
- Bollenstreekfonds, Lisse
Zitieren
APA
Andour, L., Hagenaars, S. C., de Groot, A. F., Krol-Warmerdam, E. M. M., Kroep, J. R., Hazelbag, H. M., Liefers, G. J., Straver, M. E., & Mesker, W. E. (2026). The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer. International Journal of Cancer, 159(4), 1056-1067. https://doi.org/10.1002/ijc.70490
Vancouver
Andour L, Hagenaars SC, de Groot AF, Krol-Warmerdam EMM, Kroep JR, Hazelbag HM, et al. The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer. International Journal of Cancer. 2026;159(4):1056-1067. doi:10.1002/ijc.70490
BibTeX
@article{Andour2026,
author = {Andour, Layla and Hagenaars, Sophie C and de Groot, Anne Florine and Krol-Warmerdam, Elly M M and Kroep, Judith R and Hazelbag, Hans Marten and Liefers, Gerrit-Jan and Straver, Marieke E and Mesker, Wilma E},
title = {The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {4},
pages = {1056--1067},
doi = {10.1002/ijc.70490}
}
EUVIMED